Cirrhotic Patients With Ascites Clinical Trial
Official title:
Evaluation of Copeptin in Patients With Cirrhosis and Ascites
Copeptin is a glycopeptide released by the post-pituitary gland. In case of decrease in blood
volume or blood pressure, it is secreted in the serum in an equimolar quantity to arginine
vasopressin (AVP) . Unlike AVP, copeptin is readily assayable in serum and its prognostic
value has been recently observed during cirrhosis. However, the pathophysiological
relationships between serum copeptin concentrations and indirect markers of inflammation are
unknown.
The main objective of this multicenter pilot study is to study the relationship between serum
copeptin and markers of inflammatory stress in cirrhotic patients with ascites. It is indeed
in this population with high-risk of complications that most need biomarkers of events (like
death) are needed. The main secondary objective is to evaluate the prognostic interest at 6
months of the variation of copeptin between day 0- day15.
The investigators wish to include prospectively 100 cirrhotic patients with ascites requiring prolonged hospitalization in the Hepato-gastroenterology departments of the Besançon, Nancy and Reims hospitals. The inclusion and follow-up periods will be six months each. At the inclusion of the patients we will evaluate the correlations between the plasma concentration of copeptin and 1 / the severity of cirrhosis (Child-Pugh and MELD scores) and serum sodium; 2 / systemic inflammation markers (CRP, leukocytes, IL-6 and lipopolysaccharides), 3 / calprotectin concentration in ascites. " ;